SMTL ID : 6wvz.1

Crystal structure of anti-MET Fab arm of amivantamab in complex with human MET

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 3.10 Å

Oligo State

hetero-1-1-1-mer

Ligands

2 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)

NAG-NAG.1: 3 residues within 4Å: Chain C: Y.3, L.5, N.7 No protein-ligand interaction detected (PLIP) NAG-NAG.3: 2 residues within 4Å: Chain C: L.142, N.164 No protein-ligand interaction detected (PLIP)

2 x NAG- NAG- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose

NAG-NAG-FUC.2: 3 residues within 4Å: Chain C: N.68, S.70, G.71 No protein-ligand interaction detected (PLIP) NAG-NAG-FUC.4: 3 residues within 4Å: Chain C: L.365, N.367, E.372 No protein-ligand interaction detected (PLIP)

1 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)

NAG.5: 1 residues within 4Å: Chain C: N.111 1 PLIP interactions: 1 interactions with chain C Hydrogen bonds: C:N.111

1 x FMT: FORMIC ACID(Non-functional Binders)

FMT.6: 2 residues within 4Å: Chain C: N.440, H.484 No protein-ligand interaction detected (PLIP)

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Neijssen, J. et al., Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. J.Biol.Chem. (2021)

Release Date

2021-04-28

Peptides

Heavy Chain of anti-MET Fab of amivantamab: A
Light Chain of anti-MET Fab of amivantamab: B
Hepatocyte growth factor receptor: C

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
H

B
L

C
M

Heavy Chain of anti-MET Fab of amivantamab

Light Chain of anti-MET Fab of amivantamab

Hepatocyte growth factor receptor

Related Entries With Identical Sequence